Related references
Note: Only part of the references are listed.Sirolimus versus cyclosporine in kidney recipients receiving Thymoglobulin®, mycophenolate mofetil and a 6-month course of steroids
M. Buechler et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2007)
The use of sirolimus in ganciclovir-resistant cytomegalovirus infections in renal transplant recipients
Kikumi Suzete Ozaki et al.
CLINICAL TRANSPLANTATION (2007)
Sirolimus exposure during the early post-transplant period reduces the risk of CMV infection relative to tacrolimus in renal allograft recipients
Abdoireza Haririan et al.
CLINICAL TRANSPLANTATION (2007)
Incidence, clinical characteristics and risk factors of late infection in solid organ transplant recipients:: Data from the RESITRA Study Group
R. San Juan et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2007)
A review of critical periods for opportunistic infection in the new transplantation era
Rafael San Juan Garrido et al.
TRANSPLANTATION (2006)
Monitoring of human cytomegalovirus-specific CD4+ and CD8+ T-cell immunity in patients receiving solid organ transplantation
G. Gerna et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2006)
Risk factors associated with cytomegalovirus infection in orthotopic liver transplant patients
L. Hoppe et al.
TRANSPLANTATION PROCEEDINGS (2006)
Impact of cytomegalovirus in organ transplant recipients in the era of antiviral prophylaxis
Ajit P. Limaye et al.
TRANSPLANTATION (2006)
Is double renal transplantation a risk factor for cytomegalovirus disease?
VJ Moreno-Cuerda et al.
TRANSPLANTATION PROCEEDINGS (2005)
Consensus document from GESITRA-SEIMC on the prevention and treatment of cytomegalovirus in transplanted patients
J Torre-Cisneros et al.
ENFERMEDADES INFECCIOSAS Y MICROBIOLOGIA CLINICA (2005)
Risk factors for invasive aspergillosis in solid-organ transplant recipients: A case-control study
J Gavalda et al.
CLINICAL INFECTIOUS DISEASES (2005)
Cyclosporine: Advantages versus disadvantages vis-a-vis tacrolimus
BD Maes et al.
TRANSPLANTATION PROCEEDINGS (2004)
Risk factors for cytomegalovirus viremia and disease developing after prophylaxis in high-risk solid-organ transplant recipients
RB Freeman et al.
TRANSPLANTATION (2004)
Impact of early cytomegalovirus infection and disease on long-term recipient and kidney graft survival
S Sagedal et al.
KIDNEY INTERNATIONAL (2004)
Late-onset cytomegalovirus disease in liver transplant recipients despite antiviral prophylaxis
AP Limaye et al.
TRANSPLANTATION (2004)
Human cytomegalovirus infection induces rapamycin-insensitive phosphorylation of downstream effectors of mTOR kinase
SB Kudchodkar et al.
JOURNAL OF VIROLOGY (2004)
Cytomegalovirus disease in high-risk transplant recipients despite ganciclovir or valganciclovir prophylaxis
E Akalin et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2003)
Primary immune responses to human CMV:: a critical role for IFN-γ-producing CD4+ T cells in protection against CMV disease
LE Gamadia et al.
BLOOD (2003)
Kidney transplantation without calcineurin inhibitor drugs: A prospective, randomized trial of sirolimus versus cyclosporin
SM Flechner et al.
TRANSPLANTATION (2002)
Allograft rejection predicts the occurrence of late-onset cytomegalovirus (CMV) disease among CMV-mismatched solid organ transplant patients receiving prophylaxis with oral ganciclovir
RR Razonable et al.
JOURNAL OF INFECTIOUS DISEASES (2001)
A prospective study of the natural course of cytomegalovirus infection and disease in renal allograft recipients
S Sagedal et al.
TRANSPLANTATION (2000)
T-cell activation follows Th1 rather than Th2 pattern in haemodialysis patients
U Sester et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2000)
Implication of advanced donor age on the outcome of liver transplantation
CK Oh et al.
CLINICAL TRANSPLANTATION (2000)
Sirolimus in association with mycophenolate mofetil induction for the prevention of acute graft rejection in renal allograft recipients
H Kreis et al.
TRANSPLANTATION (2000)
The influence of mycophenolate mofetil on the incidence and severity of primary cytomegalovirus infections and disease after renal transplantation
CG ter Meulen et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2000)
Initiation of hemodialysis treatment leads to improvement of T-cell activation in patients with end-stage renal disease
H Kaul et al.
AMERICAN JOURNAL OF KIDNEY DISEASES (2000)